Seres Therapeutics Inc.

09/07/2022 | Press release | Distributed by Public on 09/07/2022 05:07

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection